Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 20, 2021

NIH to enter Phase II of Covid-19 biomarker development contract

The National Institutes of Health (NIH) unit National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) are set to enter Phase II of a multi-phase contract to advance physIQ’s artificial intelligence (AI)-based digital biomarker development for Covid-19.

The National Institutes of Health (NIH) unit National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) are set to enter Phase II of a multi-phase contract to advance physIQ’s artificial intelligence (AI)-based digital biomarker development for Covid-19.

NCI and NIBIB exercised their option to enter the phase, which brings the total contract to $6.6m.

Being developed to address the fast decompensation of high-risk Covid-19 patients, the tool collects and assesses continuous physiologic data, which can potentially offer early clinical indicators of Covid-19 decompensation.

In Phase I of DeCODe study, physIQ enrolled and analysed 400 high-risk Covid-19 patients in ten weeks.

Using machine learning, the Covid-19 digital biomarker was developed and tested and is based on Phase I data.

In partnership with University of Illinois Hospital and Health Sciences System (UI Health), the DeCODe project will develop an early warning system that enables providers to intervene if the condition of a Covid-19 patient who is clinically surveilled from home is worsening.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

Continuous multi-parameter vital signs and physiological features were used to establish a targeted biomarker or Covid-19 Decompensation Index (CDI) for worsening Covid-19.

physIQ chief science officer Stephan Wegerich said: “Using Phase I data, we developed and tested a preliminary digital biomarker, using state of the art machine learning algorithms that take advantage of our extensive library of wearable biosensor analytics as inputs.

“Furthermore, we were able to demonstrate performance levels that far exceeded our target performance criterion. We are looking forward to further validation in Phase II.”

The company noted that Phase II will start this month and enrol 1,200 patients for validating the digital biomarker.

Furthermore, in the validation phase, physIQ will enrol ambulatory Covid-19 patients and analyse the digital biomarker’s ability in predicting decompensation severity remotely.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU